Inventiva S.A. Announces June 2026 General Meeting and 2025 Financial Results Approval

Inventiva S.A. filed a Form 6-K on June 12, 2026, announcing its Ordinary and Extraordinary General Meeting scheduled for June 30, 2026, in Paris. The meeting's agenda includes the approval of the fiscal year 2025 financial statements, which reported a net accounting loss of EUR 207,965,630.56. Shareholders will vote on several key resolutions, including the renewal of director mandates for Ms. Renée Aguiar-Lucander and Mr. Heinz Maeusli, and the appointment of three new directors: Ms. Camilla Soenderby, Ms. Anne Prener, and Ms. Barbara Krebs-Pohl. Additionally, the Board is seeking authorizations for various capital-raising activities. These include delegations to increase share capital with or without preemptive rights, an "At-the-market" (ATM) equity financing agreement for the US market, and the issuance of warrants to the European Investment Bank. The Board also seeks approval for a share buyback program and the authority to reduce share capital via share cancellation. Other items include executive compensation approvals and the ratification of a subscription agreement with Samsara BioCapital L.P. signed in May 2025.